Clinical Trials Logo

Filter by:
  • Approved for marketing  
  • Page [1]
NCT ID: NCT00130897 Approved for marketing - Clinical trials for Carcinoma, Renal Cell

Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma

Start date: July 2005
Phase: N/A
Study type: Expanded Access

The primary objective of this protocol is to provide access to SU011248 treatment for patients with metastatic RCC who are ineligible for participation in ongoing SU011248 clinical studies and have the potential to derive clinical benefit from treatment with SU011248 based on the judgment of the investigator.

NCT ID: NCT00040625 Approved for marketing - Mesothelioma Clinical Trials

ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.

Start date: n/a
Phase: Phase 2
Study type: Expanded Access

This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.